Clinical Trial Update: CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating a combination of CAR-T cell therapy with mosunetuzumab and polatuzumab for refractory/relapsed aggressive non-Hodgkin lym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CAR-T cell therapy
• Mosunetuzumab (mosunetuzumab)
• Polatuzumab

Snippet

Sponsor: Lazaros Lekakis | Conditions: Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma | Phase 2 | Status: RECRUITING